Enhanced tumor metastasis in response to blockade of the chemokine receptor cxcr6 is overcome by NKT cell activation

Journal of Immunology

Volumn 183, Issue 9, 2009, Pages 5807-5815

  Cullen, Robyn ^a   Germanov, Elitza ^a   Shimaoka, Takeshi ^b   Johnston, Brent ^a  

^a DALHOUSIE UNIVERSITY   (Canada)

^b UNIVERSITY OF TOKYO   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA GALACTOSYLCERAMIDE; CHEMOKINE RECEPTOR CXCR6; CXCL16 CHEMOKINE ANTIBODY; GAMMA INTERFERON; INTERLEUKIN 12; INTERLEUKIN 13; INTERLEUKIN 2; INTERLEUKIN 4; NEUTRALIZING ANTIBODY; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ATTENUATION; CELL COUNT; CONTROLLED STUDY; CYTOKINE PRODUCTION; IMMUNE RESPONSE; IMMUNITY; LEWIS CARCINOMA; LIVER METASTASIS; LUNG METASTASIS; MELANOMA B16; MOUSE; NATURAL KILLER T CELL; NONHUMAN; PRIORITY JOURNAL; TH1 CELL; TUMOR CELL; WILD TYPE;

ANIMALS; CARCINOMA, LEWIS LUNG; CELL LINE, TUMOR; LIVER NEOPLASMS, EXPERIMENTAL; LUNG NEOPLASMS; LYMPHOCYTE ACTIVATION; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; NATURAL KILLER T-CELLS; RECEPTORS, CXCR;

EID: 77954154088     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.0803520     Document Type: Article

References (60)

1. Seino, K., S. Motohashi, T. Fujisawa, T. Nakayama, and M. Taniguchi. 2006. Natural killer T cell-mediated antitumor immune responses and their clinical applications. Cancer Sci. 97: 807-812.
2. Swann, J. B., J. M. Coquet, M. J. Smyth, and D. I. Godfrey. 2007. CD1-restricted T cells and tumor immunity. Curr. Top. Microbiol. Immunol. 314: 293-323.
3. - subset. J. Exp. Med. 177: 1763-1771.
4. - α/β T cells demonstrates preferential use of several Vβ genes and an invariant TCRα chain. J. Exp. Med. 178: 1-16.
5. - T cells in mice and humans. J. Exp. Med. 180: 1097-1106.
6. - T cells. J. Exp. Med. 180: 1171-1176.
7. Benlagha, K., A. Weiss, A. Beavis, L. Teyton, and A. Bendelac. 2000. In vivo identification of glycolipid antigen-specific T cells using fluorescent CD1d tetramers. J. Exp. Med. 191: 1895-1903.
8. Matsuda, J. L., O. V. Naidenko, L. Gapin, T. Nakayama, M. Taniguchi, C. R. Wang, Y. Koezuka, and M. Kronenberg. 2000. Tracking the response of natural killer T cells to a glycolipid antigen using CD1d tetramers. J. Exp. Med. 192: 741-754.
9. Fujii, S., K. Shimizu, M. Kronenberg, and R. M. Steinman. 2002. Prolonged IFN-γ-producing NKT response induced with α-galactosylceramide- loaded DCs. Nat. Immunol. 3: 867-874.
10. Matsuda, J. L., L. Gapin, J. L. Baron, S. Sidobre, D. B. Stetson, M. Mohrs, R. M. Locksley, and M. Kronenberg. 2003. Mouse Vα14i natural killer T cells are resistant to cytokine polarization in vivo. Proc. Natl. Acad. Sci. USA 100: 8395-8400.
11. Crowe, N. Y., A. P. Uldrich, K. Kyparissoudis, K. J. Hammond, Y. Hayakawa, S. Sidobre, R. Keating, M. Kronenberg, M. J. Smyth, and D. I. Godfrey. 2003. Glycolipid antigen drives rapid expansion and sustained cytokine production by NK T cells. J. Immunol. 171: 4020-4027.
12. Van Kaer, L. 2005. α-Galactosylceramide therapy for autoimmune diseases: prospects and obstacles. Nat. Rev. Immunol. 5: 31-42.
13. Tupin, E., Y. Kinjo, and M. Kronenberg. 2007. The unique role of natural killer T cells in the response to microorganisms. Nat. Rev. Microbiol. 5: 405-417.
14. Nowak, M., and J. Stein-Streilein. 2007. Invariant NKT cells and tolerance. Int. Rev. Immunol. 26: 95-119.
15. Cui, J., T. Shin, T. Kawano, H. Sato, E. Kondo, I. Toura, Y. Kaneko, H. Koseki, M. Kanno, and M. Taniguchi. 1997. Requirement for Vα14 NKT cells in IL-12- mediated rejection of tumors. Science 278: 1623-1626.
16. Kawano, T., J. Cui, Y. Koezuka, I. Toura, Y. Kaneko, H. Sato, E. Kondo, M. Harada, H. Koseki, T. Nakayama, Y. Tanaka, and M. Taniguchi. 1998. Natural killer-like nonspecific tumor cell lysis mediated by specific ligand-activated Vα14 NKT cells. Proc. Natl. Acad. Sci. USA 95: 5690-5693.
17. Toura, I., T. Kawano, Y. Akutsu, T. Nakayama, T. Ochiai, and M. Taniguchi. 1999. Cutting edge: inhibition of experimental tumor metastasis by dendritic cells pulsed with α-galactosylceramide. J. Immunol. 163: 2387-2391. (Pubitemid 29399156)
18. Smyth, M. J., K. Y. Thia, S. E. Street, E. Cretney, J. A. Trapani, M. Taniguchi, T. Kawano, S. B. Pelikan, N. Y. Crowe, and D. I. Godfrey. 2000. Differential tumor surveillance by natural killer (NK) and NKT cells. J. Exp. Med. 191: 661-668.
19. Smyth, M. J., M. Taniguchi, and S. E. Street. 2000. The anti-tumor activity of IL-12: mechanisms of innate immunity that are model and dose dependent. J. Immunol. 165: 2665-2670.
20. Nakagawa, R., I. Nagafune, Y. Tazunoki, H. Ehara, H. Tomura, R. Iijima, K. Motoki, M. Kamishohara, and S. Seki. 2001. Mechanisms of the antimetastatic effect in the liver and of the hepatocyte injury induced by α- galactosylceramide in mice. J. Immunol. 166: 6578-6584.
21. + T cells and natural killer cells is essential for the antimetastatic effect of α-galactosylceramide. Blood 99: 1259-1266.
22. + T cells for the antitumor immunity induced in the liver of mice by α-galactosylceramide. J. Immunol. 172: 6550-6557.
23. Tachibana, T., H. Onodera, T. Tsuruyama, A. Mori, S. Nagayama, H. Hiai, and M. Imamura. 2005. Increased intratumor Vα24-positive natural killer T cells: a prognostic factor for primary colorectal carcinomas. Clin. Cancer Res. 11: 7322-7327.
24. Matloubian, M., A. David, S. Engel, J. E. Ryan, and J. G. Cyster. 2000. A transmembrane CXC chemokine is a ligand for HIV-coreceptor Bonzo. Nat. Immunol. 1: 298-304.
25. + NKT cell subsets with distinct cytokine-producing capacity. Blood 100: 11-16.
26. Lee, P. T., K. Benlagha, L. Teyton, and A. Bendelac. 2002. Distinct functional lineages of human Vα24 natural killer T cells. J. Exp. Med. 195: 637-641.
27. Motsinger, A., D. W. Haas, A. K. Stanic, L. Van Kaer, S. Joyce, and D. Unutmaz. 2002. CD1d-restricted human natural killer T cells are highly susceptible to human immunodeficiency virus 1 infection. J. Exp. Med. 195: 869-879.
28. Thomas, S. Y., R. Hou, J. E. Boyson, T. K. Means, C. Hess, D. P. Olson, J. L. Strominger, M. B. Brenner, J. E. Gumperz, S. B. Wilson, and A. D. Luster. 2003. CD1d-restricted NKT cells express a chemokine receptor profile indicative of Th1-type inflammatory homing cells. J. Immunol. 171: 2571-2580.
29. Johnston, B., C. H. Kim, D. Soler, M. Emoto, and E. C. Butcher. 2003. Differential chemokine responses and homing patterns of murine TCRαβ NKT cell subsets. J. Immunol. 171: 2960-2969. (Pubitemid 37093518)
30. + NKT cells patrolling liver sinusoids. PLoS. Biol. 3: e113.
31. Germanov, E., L. Veinotte, R. Cullen, E. Chamberlain, E. C. Butcher, and B. Johnston. 2008. Critical role for the chemokine receptor CXCR6 in homeostasis and activation of CD1d-restricted NKT cells. J. Immunol. 181: 81-91.
32. Shimaoka, T., K. Seino, N. Kume, M. Minami, C. Nishime, M. Suematsu, T. Kita, M. Taniguchi, K. Matsushima, and S. Yonehara. 2007. Critical role for CXC chemokine ligand 16 (SR-PSOX) in Th1 response mediated by NKT cells. J. Immunol. 179: 8172-8179.
33. Jiang, X., T. Shimaoka, S. Kojo, M. Harada, H. Watarai, H. Wakao, N. Ohkohchi, S. Yonehara, M. Taniguchi, and K. Seino. 2005. Cutting edge: critical role of CXCL16/CXCR6 in NKT cell trafficking in allograft tolerance. J. Immunol. 175: 2051-2055.
34. Unutmaz, D., W. Xiang, M. J. Sunshine, J. Campbell, E. Butcher, and D. R. Littman. 2000. The primate lentiviral receptor Bonzo/STRL33 is coordinately regulated with CCR5 and its expression pattern is conserved between human and mouse. J. Immunol. 165: 3284-3292.
35. Kopper, L., H. T. Van, and K. Lapis. 1982. Experimental model for liver metastasis formation using Lewis lung tumor. J. Cancer Res. Clin. Oncol. 103: 31-38.
36. Fidler, I. J. 1975. Biological behavior of malignant melanoma cells correlated to their survival in vivo. Cancer Res. 35: 218-224.
37. Crowe, N. Y., J. M. Coquet, S. P. Berzins, K. Kyparissoudis, R. Keating, D. G. Pellicci, Y. Hayakawa, D. I. Godfrey, and M. J. Smyth. 2005. Differential antitumor immunity mediated by NKT cell subsets in vivo. J. Exp. Med. 202: 1279-1288.
38. Schmieg, J., G. Yang, R. W. Franck, and M. Tsuji. 2003. Superior protection against malaria and melanoma metastases by a C-glycoside analogue of the natural killer T cell ligand α-galactosylceramide. J. Exp. Med. 198: 1631-1641.
39. Fujii, S., K. Shimizu, H. Hemmi, M. Fukui, A. J. Bonito, G. Chen, R. W. Franck, M. Tsuji, and R. M. Steinman. 2006. Glycolipid α-C- galactosylceramide is a distinct inducer of dendritic cell function during innate and adaptive immune responses of mice. Proc. Natl. Acad. Sci. USA 103: 11252-11257.
40. Miyamoto, K., S. Miyake, and T. Yamamura. 2001. A synthetic glycolipid prevents autoimmune encephalomyelitis by inducing TH2 bias of natural killer T cells. Nature 413: 531-534.
41. Chiba, A., S. Oki, K. Miyamoto, H. Hashimoto, T. Yamamura, and S. Miyake. 2004. Suppression of collagen-induced arthritis by natural killer T cell activation with OCH, a sphingosine-truncated analog of α- galactosylceramide. Arthritis Rheum. 50: 305-313.
42. Parekh, V. V., M. T. Wilson, D. Olivares-Villagomez, A. K. Singh, L. Wu, C. R. Wang, S. Joyce, and K. L. Van. 2005. Glycolipid antigen induces long-term natural killer T cell anergy in mice. J. Clin. Invest. 115: 2572-2583.
43. Uldrich, A. P., N. Y. Crowe, K. Kyparissoudis, D. G. Pellicci, Y. Zhan, A. M. Lew, P. Bouillet, A. Strasser, M. J. Smyth, and D. I. Godfrey. 2005. NKT cell stimulation with glycolipid antigen in vivo: costimulation-dependent expansion, Bim-dependent contraction, and hyporesponsiveness to further antigenic challenge. J. Immunol. 175: 3092-3101.
44. Parekh, V. V., S. Lalani, S. Kim, R. Halder, M. Azuma, H. Yagita, V. Kumar, L. Wu, and L. V. Kaer. 2009. PD-1/PD-L blockade prevents anergy induction and enhances the anti-tumor activities of glycolipid-activated invariant NKT cells. J. Immunol. 182: 2816-2826.
45. Oki, S., A. Chiba, T. Yamamura, and S. Miyake. 2004. The clinical implication and molecular mechanism of preferential IL-4 production by modified glycolipidstimulated NKT cells. J. Clin. Invest. 113: 1631-1640.
46. Goff, R. D., Y. Gao, J. Mattner, D. Zhou, N. Yin, C. Cantu, III, L. Teyton, A. Bendelac, and P. B. Savage. 2004. Effects of lipid chain lengths in α-galactosylceramides on cytokine release by natural killer T cells. J. Am. Chem. Soc. 126: 13602-13603.
47. Bai, L., Y. Sagiv, Y. Liu, S. Freigang, K. O. Yu, L. Teyton, S. A. Porcelli, P. B. Savage, and A. Bendelac. 2009. Lysosomal recycling terminates CD1d-mediated presentation of short and polyunsaturated variants of the NKT cell lipid antigen αGalCer. Proc. Natl. Acad. Sci. USA 106: 10254-10259.
48. Tahir, S. M., O. Cheng, A. Shaulov, Y. Koezuka, G. J. Bubley, S. B. Wilson, S. P. Balk, and M. A. Exley. 2001. Loss of IFN-γ production by invariant NK T cells in advanced cancer. J. Immunol. 167: 4046-4050.
49. Giaccone, G., C. J. Punt, Y. Ando, R. Ruijter, N. Nishi, M. Peters, B. M. von Blomberg, R. J. Scheper, H. J. van der Vliet, A. J. van den Eertwegh, et al. 2002. A phase I study of the natural killer T-cell ligand α-galactosylceramide (KRN7000) in patients with solid tumors. Clin. Cancer Res. 8: 3702-3709.
50. Kenna, T., L. G. Mason, S. A. Porcelli, Y. Koezuka, J. E. Hegarty, C. O'Farrelly, and D. G. Doherty. 2003. NKT cells from normal and tumor-bearing human livers are phenotypically and functionally distinct from murine NKT cells. J. Immunol. 171: 1775-1779.
51. Dhodapkar, M. V., M. D. Geller, D. H. Chang, K. Shimizu, S. Fujii, K. M. Dhodapkar, and J. Krasovsky. 2003. A reversible defect in natural killer T cell function characterizes the progression of premalignant to malignant multiple myeloma. J. Exp. Med. 197: 1667-1676.
52. + NKT cell numbers are decreased in cancer patients independent of tumor type or tumor load. Int. J. Cancer 116: 87-93.
53. Wu, D. Y., N. H. Segal, S. Sidobre, M. Kronenberg, and P. B. Chapman. 2003. Cross-presentation of disialoganglioside GD3 to natural killer T cells. J. Exp. Med. 198: 173-181.
54. Ishii, R., M. Shimizu, Y. Nakagawa, K. Shimizu, S. Tanaka, and H. Takahashi. 2004. In vivo priming of natural killer T cells by dendritic cells pulsed with hepatoma-derived acid-eluted substances. Cancer Immunol. Immunother. 53: 383-390.
55. Wilbanks, A., S. C. Zondlo, K. Murphy, S. Mak, D. Soler, P. Langdon, D. P. Andrew, L. Wu, and M. Briskin. 2001. Expression cloning of the STRL33/ BONZO/TYMSTR ligand reveals elements of CC, CXC, and CX3C chemokines. J. Immunol. 166: 5145-5154.
56. Kim, C. H., E. J. Kunkel, J. Boisvert, B. Johnston, J. J. Campbell, M. C. Genovese, H. B. Greenberg, and E. C. Butcher. 2001. Bonzo/CXCR6 expression defines type 1-polarized T-cell subsets with extralymphoid tissue homing potential. J. Clin. Invest. 107: 595-601.
57. + lymphocytes to inflamed liver. J. Immunol. 174: 277-283.
58. Fukumoto, N., T. Shimaoka, H. Fujimura, S. Sakoda, M. Tanaka, T. Kita, and S. Yonehara. 2004. Critical roles of CXC chemokine ligand 16/scavenger receptor that binds phosphatidylserine and oxidized lipoprotein in the pathogenesis of both acute and adoptive transfer experimental autoimmune encephalomyelitis. J. Immunol. 173: 1620-1627.
59. Terabe, M., S. Matsui, N. Noben-Trauth, H. Chen, C. Watson, D. D. Donaldson, D. P. Carbone, W. E. Paul, and J. A. Berzofsky. 2000. NKT cell-mediated repression of tumor immunosurveillance by IL-13 and the IL-4R-STAT6 pathway. Nat. Immunol. 1: 515-520.
60. + NKT regulatory cells and IL-13. Int. J. Cancer 114: 80-87.